Effect of olanzapine on hyperemesis gravidarum in individuals with mood disorders: A case series

Verinder Sharma; Katelyn N Wood

doi:10.1016/j.jogc.2024.102751

Effect of olanzapine on hyperemesis gravidarum in individuals with mood disorders: A case series

J Obstet Gynaecol Can. 2024 Dec 20:102751. doi: 10.1016/j.jogc.2024.102751. Online ahead of print.

Authors

Verinder Sharma¹, Katelyn N Wood²

Affiliations

¹ Department of Psychiatry, Western University, London, Ontario, Canada; Department of Obstetrics & Gynecology, Western University, London, Ontario, Canada; Parkwood Institute Mental Health, St. Joseph's Health Care, London, Ontario, Canada. Electronic address: vsharma@uwo.ca.
² Parkwood Institute Mental Health, St. Joseph's Health Care, London, Ontario, Canada.

PMID: 39710290
DOI: 10.1016/j.jogc.2024.102751

Abstract

This case series examines the effect of olanzapine on symptoms of hyperemesis gravidarum in individuals with mood disorders. Patient charts from 2022 to 2024 were reviewed, focusing on those with hyperemesis gravidarum who were treated with olanzapine alone or with other psychotropic drugs for their mood disorder. Of 6 patients with hyperemesis gravidarum, 3 had bipolar II disorder, and the others had major depressive disorder. Olanzapine was used alone in 3 cases. A daily dose of 2.5-5 mg was well tolerated and effective in all patients who had failed trials of conventional antiemetics. Thus, olanzapine may be a viable treatment for hyperemesis gravidarum in mood disorder patients unresponsive to standard antiemetics.

Keywords: depression; hyperemesis gravidarum; olanzapine; treatment.